Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Forte Biosciences is a clinical-stage biopharmaceutical company developing immunomodulatory therapies targeting autoimmune diseases. Its lead candidate, FB102, is a monoclonal antibody aimed at conditions like celiac disease, vitiligo, alopecia areata, and type 1 diabetes. The company focuses on innovative biologics, regulatory approval processes, and strategic partnerships to address unmet medical needs in autoimmune markets.
This description was generated via AI from an annual report. Updated about 1 year ago.